Kevin O'Shaughnessy

Prof. Dr. Kevin O'Shaughnessy

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2010 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
FRFatema H. Rafiqi
Fatema H. Rafiqi
AZAnnie Mercier Zuber
Annie Mercier Zuber
MGMark Glover
Mark Glover
CRCiaran Richardson
Ciaran Richardson
SFStewart Fleming
Stewart Fleming
DADario R. Alessi
Dario R. Alessi
Mutations within the with‐no‐K(Lys) (WNK) kinases cause Gordon's syndrome characterized by hypertension and hyperkalaemia. WNK kinases phosphorylate and activate the STE20/SPS1‐related proline/alanine‐rich kinase (SPAK) protein kinase, which phosphorylates and stimulates the key Na+:Cl− cotransporter (NCC) and Na+:K+:2Cl− cotransporters (NKCC2) cotransporters that control salt reabsorption in the kidney. To define the importance of this pathway in regulating blood pressure, we generated knock‐in mice in which SPAK cannot be activated by WNKs. The SPAK knock‐in animals are viable, but display significantly reduced blood pressure that was salt‐dependent. These animals also have markedly reduced phosphorylation of NCC and NKCC2 cotransporters at the residues phosphorylated by SPAK. This was also accompanied by a reduction in the expression of NCC and NKCC2 protein without changes in messenger RNA (mRNA) levels. On a normal Na+‐diet, the SPAK knock‐in mice were normokalaemic, but developed mild hypokalaemia when the renin–angiotensin system was activated by a low Na+‐diet. These observations establish that SPAK plays an important role in controlling blood pressure in mammals. Our results imply that SPAK inhibitors would be effective at reducing blood pressure by lowering phosphorylation as well as expression of NCC and NKCC2. See accompanying Closeup by Maria Castañeda‐Bueno and Gerald Gamba (DOI 10.1002/emmm.200900059).

18 August 2015 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
FSFrances‐Rose Schumacher
Frances‐Rose Schumacher
KSKeith Siew
Keith Siew
JZJinwei Zhang
Jinwei Zhang
CJClare Johnson
Clare Johnson
NWNicola Wood
Nicola Wood
TKThimo Kurz
Thimo Kurz
Deletion of exon 9 from Cullin‐3 (CUL3, residues 403–459: CUL3 Δ403–459 ) causes pseudohypoaldosteronism type IIE (PHA2E), a severe form of familial hyperkalaemia and hypertension (FHHt). CUL3 binds the RING protein RBX1 and various substrate adaptors to form Cullin‐RING‐ubiquitin‐ligase complexes. Bound to KLHL3, CUL3‐RBX1 ubiquitylates WNK kinases, promoting their ubiquitin‐mediated proteasomal degradation. Since WNK kinases activate Na/Cl co‐transporters to promote salt retention, CUL3 regulates blood pressure. Mutations in both KLHL3 and WNK kinases cause PHA2 by disrupting Cullin‐RING‐ligase formation. We report here that the PHA2E mutant, CUL3 Δ403–459 , is severely compromised in its ability to ubiquitylate WNKs, possibly due to altered structural flexibility. Instead, CUL3 Δ403–459 auto‐ubiquitylates and loses interaction with two important Cullin regulators: the COP9‐signalosome and CAND1. A novel knock‐in mouse model of CUL3 WT /Δ403–459 closely recapitulates the human PHA2E phenotype. These mice also show changes in the arterial pulse waveform, suggesting a vascular contribution to their hypertension not reported in previous FHHt models. These findings may explain the severity of the FHHt phenotype caused by CUL3 mutations compared to those reported in KLHL3 or WNK kinases.

11 December 2014 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
KOKevin O'Shaughnessy
Kevin O'Shaughnessy

1 June 1999 in Hypertension
Verified
Journal Article
Closed access
KOKevin O'Shaughnessy
Kevin O'Shaughnessy
BFBeiyuan Fu
Beiyuan Fu
FFFranco Ferraro
Franco Ferraro
ILIan Lewis
Ian Lewis
SDSarah Downing
Sarah Downing
NMNick H. Morris
Nick H. Morris
—Preeclampsia is a heritable condition that develops as a result of widespread vascular endothelial dysfunction. The thrombotic tendency in this condition has suggested a number of candidate genes, and there have been recent reports of positive association with the Leiden variant of factor V and the thermolabile variant of methylenetetrahydrofolate reductase. We attempted to reproduce these results in a large cohort of well-characterized women with preeclampsia, recruited prospectively within the East Anglian region of the United Kingdom. Women in the preeclampsia cohort (n=283) were genotyped for both the Leiden variant (G1691A) of factor V and the thermolabile variant (C677T) of methylenetetrahydrofolate reductase. Genotype and allele frequencies were compared with those of 2 control groups, one consisting of women recruited prospectively (n=100) from the same maternity hospital as the subjects and another consisting of normotensive women (n=100) from East Anglia. No significant differences were detected. Specifically, the carrier rate for the Leiden variant was 5.3% in the preeclampsia group and 5.5% in the combined control group. T677 homozygotes for methylenetetrahydrofolate reductase were 11% and 11.5% in the 2 groups, respectively. We conclude that there is no evidence of association of preeclampsia with either of these 2 polymorphisms in our study population.

1 December 2006 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Open access
PDF file
AGAmir P. Golbang
Amir P. Golbang
GCGeorgina Cope
Georgina Cope
AHAbbas Hamad
Abbas Hamad
MMMeena Murthy
Meena Murthy
CLChe-Hsiung Liu
Che-Hsiung Liu
KOKevin O'Shaughnessy
Kevin O'Shaughnessy
The novel serine/threonine kinases (with no lysine kinases or WNKs), WNK1 and WNK4, are encoded by the disease genes for Gordon syndrome (PRKWNK1 and PRKWNK4), a rare monogenic syndrome of hypertension and hyperkalemia. These proteins alter the expression of the thiazide-sensitive Na/Cl cotransporter (NCCT) in Xenopus laevis oocytes, although the details are controversial. We describe here our own experience and confirm that kinase-dead WNK4 (318D>A) is unable to affect Na+fluxes through the thiazide-sensitive Na/Cl transporter (NCCT) or its membrane expression as an ECFP-NCCT fusion protein. However, the kinase domain is not sufficient for a functional WNK4 since deletion of the acidic motif (a motif unique to WNK family members) completely abolishes functional activity. Indeed, the NH2terminal of WNK4 (1–620) containing the kinase domain and acidic motif retains full activity, but does not interact directly with NCCT in pull-down assays. Coexpression of WNK1 antagonizes the action of WNK4, and kinase-dead WNK1 (368D>A) or WNK1 carrying a WNK4 disease mutation (565Q>E) behaves in the same way as wild-type WNK1. This suggests kinase activity and charge conservation within the acidic motif are not essential for the WNK1-WNK4 interaction. We also report that WNK4 probably reduces surface expression largely through an effect on forward trafficking. Hence, the effect of WNK4 on NCCT expression is mimicked by dynamin, but the dominant-negative K44A dynamin mutant does not block the action of WNK4 itself. These results further highlight important differences in the mechanism by which WNK kinases affect expression of NCCT vs. other membrane proteins such as ROMK.

11 June 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
KSKeith Siew
Keith Siew
KNKevin A Nestler
Kevin A Nestler
CNCharlotte Nelson
Charlotte Nelson
VDViola D'Ambrosio
Viola D'Ambrosio
CZChutong Zhong
Chutong Zhong
SWStephen B Walsh
Stephen B Walsh
Missions into Deep Space are planned this decade. Yet the health consequences of exposure to microgravity and galactic cosmic radiation (GCR) over years-long missions on indispensable visceral organs such as the kidney are largely unexplored. We performed biomolecular (epigenomic, transcriptomic, proteomic, epiproteomic, metabolomic, metagenomic), clinical chemistry (electrolytes, endocrinology, biochemistry) and morphometry (histology, 3D imaging, miRNA-ISH, tissue weights) analyses using samples and datasets available from 11 spaceflight-exposed mouse and 5 human, 1 simulated microgravity rat and 4 simulated GCR-exposed mouse missions. We found that spaceflight induces: 1) renal transporter dephosphorylation which may indicate astronauts’ increased risk of nephrolithiasis is in part a primary renal phenomenon rather than solely a secondary consequence of bone loss; 2) remodelling of the nephron that results in expansion of distal convoluted tubule size but loss of overall tubule density; 3) renal damage and dysfunction when exposed to a Mars roundtrip dose-equivalent of simulated GCR.